Molecular Tumor Board: 44-year-old male with advanced NSCLC and ROS1 fusion

This Molecular Tumor Board, our Oncology Medical Affairs team reviews concurrent tissue- and plasma-based comprehensive NGS testing for the management of a young patient with advanced stage NSCLC. A growing number of guideline-recommended biomarkers are reviewed for frontline targeted therapy selection and prevalence of oncogenic driver alterations in NSCLC. The process of utilizing and optimizing cytology specimens for NGS analysis is also discussed.

Colorectal cancer: How to increase screening compliance rates

Watch subject matter experts Aasma Shaukat, MD, MPH, and Erin Peterson from the Colon Cancer Coalition address how to capture patient compliance for colorectal cancer screenings, gain early detection and improve patient outcomes.

Multiple myeloma: How primary care can support early myeloma detection

Hear from multiple myeloma subject matter experts Joseph Michael, MD, Med, FRCPC, FACP, and Saad Usmani, MD, MBA, FACP, FASCO, on early detection and referral to hematology for improved patient outcomes.

Preeclampsia risk assessment across all trimesters using blood-based biochemical markers

Hear from our subject matter experts about the latest breakthrough biomarkers to help in the risk assessment and clinical management of preeclampsia across U.S. patient populations across all trimesters.

Multiple myeloma: Empowering the frontline – confronting a deceptive cancer affecting vulnerable communities

Multiple Myeloma: Empowering the Frontline – Confronting a Deceptive Cancer Affecting Vulnerable Communities

Urine drug testing for medication-assisted treatment (MAT)

Treatment professionals agree that monitoring drug use during MAT can be a powerful incentive for abstinence, and it can also help identify OUD relapse.

Evolving drug trends and spotlight on xylazine

During this webinar, our toxicology experts provide an informative and fascinating review of the ever-changing landscape of the illicit drug market. Labcorp’s R&D scientific director shares insights related to the history of designer drugs, new uses for age-old drugs and how Labcorp responds to evolving drug trends. Most importantly we discuss the relevance of these drug trends in routine clinical practice.

NfL in Real-World Clinical Settings

LabCorp Insight Analytics (CHI@Home 2020)

NIH LDL Cholesterol Calculation